Alfuzosin

Generic Name: Alfuzosin

Brand Names: Uroxatral, Xatral

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₇N_₅O_₄

CAS Number: 81403-80-7

Unique Ingredient Identifier: 90347YTW5F

Background: Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.

Indication: Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).

Associated Conditions: Benign Prostatic Hyperplasia (BPH)

Associated Therapies: -

Clinical Trials

Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia

Not Applicable

Completed

Conditions: Benign Prostatic Hypertrophy With Outflow Obstruction
Benign Prostatic Hyperplasia

Interventions: Dietary Supplement: Odyliresin
Drug: Alfuzosin

First Posted Date: 2016-11-30

Last Posted Date: 2017-02-28

Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Target Recruit Count: 30

Registration Number: NCT02977832

Locations: 🇮🇹
Urology Department Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Tamsulosin
Drug: Alfuzosin
Drug: Doxazosin

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 97

Registration Number: NCT02266537

Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

Phase 2

Completed

Conditions: Constipation

Interventions: Other: Placebo
Drug: Alfuzosin

First Posted Date: 2013-04-18

Last Posted Date: 2019-01-29

Lead Sponsor: Mayo Clinic

Target Recruit Count: 74

Registration Number: NCT01834729

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Phase 3

Completed

Conditions: Lower Urinary Tract Symptoms
Erectile Dysfunction

Interventions: Drug: Placebo
Drug: Alfuzosin

First Posted Date: 2009-05-05

Last Posted Date: 2018-03-09

Lead Sponsor: Chesapeake Urology Research Associates

Target Recruit Count: 74

Registration Number: NCT00893113

Locations: 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States

Evaluation of Symptom-specific Goal Achievement

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia
Lower Urinary Tract Symptoms

Interventions: Drug: Alfuzosin

First Posted Date: 2009-02-04

Last Posted Date: 2023-11-01

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 130

Registration Number: NCT00836823

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

Phase 3

Conditions: Kidney Stones

Interventions: Drug: Alfuzosin
Drug: nifedipine
Drug: doxazosin
Drug: prazosin

First Posted Date: 2008-07-11

Last Posted Date: 2012-04-27

Lead Sponsor: United States Naval Medical Center, San Diego

Target Recruit Count: 240

Registration Number: NCT00713739

Locations: 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States

The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

Phase 4

Completed

Conditions: BPH

Interventions: Drug: Alfuzosin

First Posted Date: 2008-06-13

Last Posted Date: 2021-02-17

Lead Sponsor: Asan Medical Center

Target Recruit Count: 232

Registration Number: NCT00696761

Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)

Phase 2

Terminated

Conditions: Multiple Sclerosis
Bladder Dysfunction

First Posted Date: 2008-06-03

Last Posted Date: 2011-06-27

Lead Sponsor: Nova Scotia Health Authority

Target Recruit Count: 20

Registration Number: NCT00688948

Locations: 🇨🇦
QE II Health Science Centre, Halifax Infirmary, Halifax, Nova Scotia, Canada

Once Daily Given Alfuzosin in the Treatment of BPH

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

First Posted Date: 2008-03-18

Last Posted Date: 2008-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 60

Registration Number: NCT00637715

Locations: 🇭🇺
Sanofi-Aventis, Budapest, Hungary

Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Phase 3

Completed

Conditions: Neurogenic Bladder
Hydronephrosis

Interventions: Drug: Alfuzosin

First Posted Date: 2007-12-19

Last Posted Date: 2014-10-29

Lead Sponsor: Sanofi

Target Recruit Count: 25

Registration Number: NCT00576823

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
🇸🇬
Sanofi-Aventis Aministrative Office, Singapore, Singapore

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy